TILT Biotherapeutics Announces Positive Clinical Data on Lead Asset TILT-123 at Society for Immunotherapy of Cancer 2023
November 06, 2023 03:00 ET
|
TILT Biotherapeutics Oy
HELSINKI, Finland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company at the forefront of developing cancer immunotherapies, presented Phase I data...
Combination Cancer Therapy Market Insight 2028
June 09, 2022 05:42 ET
|
KuicK Research
Singapore, June 09, 2022 (GLOBE NEWSWIRE) -- Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights: Global & Regional Combination...